Biological Activity of Netilmicin, a Broad-Spectrum Semisynthetic Aminoglycoside Antibiotic
AUTOR(ES)
Miller, George H.
RESUMO
Netilmicin (Sch 20569) is a new broad-spectrum semisynthetic aminoglycoside derived from sisomicin. Netilmicin was compared to gentamicin, tobramycin, and amikacin in a variety of in vitro test systems as well as in mouse protection tests. Netilmicin was found to be similar in activity to gentamicin against aminoglycoside-susceptible strains in both in vitro and in vivo tests. Netilmicin was also active against many aminoglycoside-resistant strains of gram-negative bacteria, particularly those known to possess adenylating enzymes (ANT 2′) or those with a similar resistance pattern. Netilmicin was found to be markedly less toxic than gentamicin in chronic studies in cats, although gentamicin appeared less toxic in acute toxicity tests in mice. The concentrations of netilmicin and gentamicin in serum were compared in dogs after intramuscular dosing, and the pharmacokinetics including peak concentrations in serum were found to be similar.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=429844Documentos Relacionados
- Pirbenicillin, a New Semisynthetic Penicillin with Broad-Spectrum Activity
- Thienamycin: New Beta-Lactam Antibiotic with Potent Broad-Spectrum Activity
- In vivo activity of ceftriaxone (Ro 13-9904), a new broad-spectrum semisynthetic cephalosporin.
- PC-904, a Novel Broad-Spectrum Semisynthetic Penicillin with Marked Antipseudomonal Activity: Microbiological Evaluation
- PC-904, a Novel Broad-Spectrum Semisynthetic Penicillin with Marked Antipseudomonal Activity: Microbiological Evaluation